Check out your Company Bowl for anonymous work chats.
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer (“CFO”) and Chief Operating Officer (“COO”), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company’s new CFO.
BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, recently reported financial results for the third quarter ended September 30, 2024.
“Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This study harnesses the power of multimodal data and advanced AI to identify which patients are most likely to benefit from specific therapies. By tailoring treatment strategies based on a patient’s unique multimodal profile, we aim to improve outcomes and offer new hope to those battling this difficult disease.”
Under the new generation of SOPHiA DDM™, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs: Genomics: Ingests genomics FASTQ and VCF data to efficiently call, annotate, and pre-classify oncogenic or pathogenic variants. Radiomics: Processes data from various imaging modalities (e.g., CT scans, PET-CT, MRI), segments anatomical areas of interest, and extracts radiomic features for further analysis. Multimodal: Aggregates data from the radiomics and genomics modules, along with processed clinical, biological, and histological data, to train and verify predictive models at the individual patient level.
“At SOPHiA GENETICS, certification of our SOPHiA DDM™ Platform under IVDR builds on our track record of offering a broad set of CE-IVD applications and giving our customers confidence in knowing they are using a cutting-edge, compliant Platform for their analysis needs,” said Daan Van Well, LL.M., M.B.A., Chief Legal and Compliance Officer SOPHiA GENETICS. “This was a top priority for our team to ensure a seamless transition for our current CE-IVD customers so they can continue to use the SOPHiA DDM™ Platform to support diagnosis and treatment decisions for patients facing cancer.”
🚀 We are extremely proud to announce the launch of MSK-ACCESS® powered with SOPHiA DDM™! Today, SOPHiA GENETICS had the pleasure to host a launch event at our Global Headquarters in Switzerland in collaboration with the Memorial Sloan Kettering Cancer Center team and open our doors to a large group of world-class healthcare and biopharma leaders, physicians, researchers, customers, and partners. We had the honor to host EMEA representatives from our network of 750+ global institutions and showcase our commitment to connecting communities and fostering cross-border collective intelligence to improve patient outcomes worldwide. In this insightful gathering, the attendees immersed themselves in the world of SOPHiA GENETICS, explored our mission of democratizing data-driven medicine through our global connected institutions’ network, and gained real-world insights from the early access data from MSK-ACCESS® powered with SOPHiA DDM™. 🙏 A heartfelt thank you to everyone who contributed to making this launch a success! #MSKACCESSpoweredwithSOPHiADDM hashtag#MSK hashtag#oncology hashtag#liquidbiopsy hashtag#datadrivenmedicine hashtag#precisiononcology
SOPHiA GENETICS reported first quarter 2024 financial results today, featuring consistent revenue growth with reported revenue of $15.8 million and a second consecutive quarter of strong new business momentum with 27 new core genomics customers signed, including 3 in countries new to the SOPHiA DDM™ network. "We delivered solid achievements in Q1 to fuel future growth,” said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder. "I am especially proud of our ability to continue to grow sustainably as we recorded yet another quarter of notable bottom-line improvements with adjusted operating loss improving 13% year-over year.”
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings. SOPHiA GENETICS today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumour mutation profiling. The rollout of SOPHiA GENETICS’ liquid biopsy capabilities demonstrates the company’s commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes.
We’re proud to share our third quarter results for 2023, featuring strong revenue growth compared to Q3 2022 with a reported $16.3 million in revenue; high volumes of analyses, with over 79,000 performed this quarter alone, and continued growth in our customer ecosystem. “We delivered an outstanding third quarter, and our growth came across the breadth of our portfolio areas and geographies, despite the currently challenging macro environment. Our strong performance was complemented by continued improvements to gross margins and operating expenses. The team at SOPHiA GENETICS continues to drive innovation and growth in the area of technology-agnostic artificial intelligence (AI) software for genomic and multimodal analysis.” Jurgi Camblong, PhD., Chief Executive Officer and Co-founder. Read more in our full earnings press release:
We're not just talking about change... We're driving it! 📣 We are proud to announce a groundbreaking collaboration between SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca. Our shared mission? Democratize access to advanced cancer testing on a global scale, aiming towards health equity for all. With #cancer as the second leading cause of death worldwide, the need for comprehensive testing is essential. This partnership will leverage MSK's proprietary tests, MSK-ACCESS® and MSK-IMPACT®, delivered via our decentralized, AI-powered, cloud-based SOPHiA DDM™ Platform, and amplified by AstraZeneca's global reach. Kristina Rodnikova, Head of Global Oncology Diagnostics, AstraZeneca, shares, “We believe that our collaboration with MSK and SOPHiA GENETICS will provide physicians and patients with the reliable data that they need to better diagnose their disease.” Anaeze Offodile II, MD, MPH, Chief Strategy Officer at Memorial Sloan Kettering Cancer Center, adds, “Expanding our advanced genomic testing to a global population generates a diverse data set to help develop treatments that could benefit different and often underserved populations.” By harnessing the power of data, we aim to provide invaluable insights that could shape the future of global healthcare. #AIinHealthcare #CollectiveIntelligence #CancerResearch #DataDrivenMedicine
